

Balance Sheet
Pola Pharma Inc.
As of December 31, 2019

Japanese yen

Asset	
Current Assets	
Cash and Deposits	706,154,301
Trade Receivable	4,353,297,930
Accounts Receivable Other	62,508,637
Inventories	2,267,451,047
Prepaid Expenses	31,642,779
Interest receivable	1,240,000
Short-term loan	3,620,000,000
Consumption tax receivable	81,370,253
Total Current Assets	11,123,664,947
Non-Current Assets	
Property and Equipment	
Buildings	63,227,900
Office Equipments	134,857,711
Accumulated Depreciation	(121,071,618)
Total Property and Equipment	77,013,993
Intangible Assets	1,855,000
Other Assets	
Long Term Prepaid Expenses	0
Shares of subsidiaries	765,915,851
Security Deposits	23,744,893
Total Other Assets	789,660,744
Total Non-Current Assets	868,529,737
Total Assets	11,992,194,684
Liabilities	
Current Liabilities	
Trade Payable	1,985,704,886
Accounts Payable Other	296,632,030
Accrued Expenses	153,373,680
Income tax payable	295,957,779
Consumption tax payable	193,819,182
Deposits received	319,206,433
Provision for Bonus	66,400,000
Other Liabilities	50,233,154
Total Current Liabilities	3,361,327,144
Non-Current Liabilities	
Total Non-Current Liabilities	1,300,499,500
Total Liability	4,661,826,644
Equity	
Equity	
Share Capital	100,000,000
Surplus	7,230,368,040
Total Equity	7,330,368,040
Total Liabilities and Equity	11,992,194,684

Income Statement

Pola Pharma Inc.

From January 1st, 2019 to December 31st, 2019

		Japanese yen
Product Sales		11,090,077,228
Cost of Product Sales		5,992,660,663
Commision		
Gross Profit		5,097,416,565
Selling, General and Administrative Expenses		
Personnel expenses		1,964,334,581
Reserch and Development		132,764,829
Depreciation and Amortization		10,176,958
Integration Cost		382,571,634
Other Operating Expenses		1,625,960,317
Total Selling, General and Administrative Expenses		4,115,808,319
Operating Profit		981,608,246
Interest Income & FX gain	10,740,637	
Miscellaneous Income	656,801	
Total Non-Operating Income		11,397,438
Interest Expense & FX loss		25,029
Miscellaneous Expenses		423,938
Total Non-Operating Expense		448,967
Ordinary Profit		992,556,717
Extraordinary profit	300,000,000	
Extaraordinary Profit		300,000,000
Profit before Tax		1,292,556,717
Income Tax		296,121,653
Net Profit		996,435,064

Statements of Shareholders' Equity

Pola Pharma Inc.

From January 1, 2019

To December 31, 2019

	Share Capital	Capital Reserve	Retained Earnings	in Japanese Yen Total Shareholders' Equity
Balance at December 31, 2018	100,000,000	6,432,019,108	(198,086,132)	6,333,932,976
Changes of items during the period				
Net Income (Loss)			996,435,064	
Total changes of items during the period	0	0	996,435,064	
<u>Balance at December 31st, 2019</u>	<u>100,000,000</u>	<u>6,432,019,108</u>	<u>798,348,932</u>	<u>7,330,368,040</u>